Lab
Western Montana Clinic PC
Western Montana Clinic PC was paid $1.70M by Medicaid between Jan 2018 and Dec 2024, across 70 billing codes. Its largest line is 84443, Thyroid stimulating hormone (TSH) — 7.0% of everything it billed.
33Billing provider infoWESTERN MONTANA CLINIC PC
MISSOULA, MT 59802
MISSOULA, MT 59802
33aNPI1740364017assigned 10/24/2006
33bProvider typeClinical Medical Laboratory
28Total paid$1.70M
24GClaims142,980
24DCodes billed70
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Montana
Rank by total paid#2 of 18
Median peer was paid$125K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,695 | $264K | |
| 2019 | 21,280 | $256K | |
| 2020 | 17,963 | $187K | |
| 2021 | 22,847 | $281K | |
| 2022 | 21,281 | $256K | |
| 2023 | 21,283 | $255K | |
| 2024incomplete | 16,631 | $199K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 84443 | Thyroid stimulating hormone (TSH) | 7.0% | 5,949 | 5,479 | $119K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 6.7% | 3,908 | 2,932 | $115K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 6.6% | 3,387 | 3,161 | $111K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 6.6% | 3,390 | 3,160 | $111K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 6.3% | 4,488 | 4,155 | $107K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 6.0% | 4,177 | 3,911 | $102K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 5.6% | 2,944 | 2,799 | $95K |
| 80053 | Comprehensive metabolic panel | 5.6% | 13,688 | 12,402 | $94K |
| 36415 | Collection of venous blood by venipuncture | 5.4% | 27,432 | 24,309 | $91K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.4% | 14,103 | 12,810 | $74K |
| 80050 | General health panel | 4.2% | 1,346 | 1,264 | $72K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 759 | 724 | $52K |
58 more codes
| 80061 | Lipid panel | 2.6% | 4,456 | $44K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.6% | 1,958 | $44K |
| 86803 | 2.2% | 2,941 | $37K | |
| 87660 | 2.0% | 1,958 | $35K | |
| 87510 | 2.0% | 1,952 | $35K | |
| 87480 | 2.0% | 1,970 | $35K | |
| 82728 | 1.4% | 2,223 | $24K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 3,456 | $24K |
| 86140 | 1.4% | 5,322 | $23K | |
| 87340 | 1.1% | 2,063 | $19K | |
| 87581 | <1% | 422 | $17K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 726 | $17K |
| 85027 | <1% | 2,784 | $15K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 428 | $14K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 157 | $13K |
| 86780 | <1% | 1,057 | $12K | |
| 81001 | <1% | 4,424 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 236 | $11K |
| 83550 | <1% | 1,424 | $10K | |
| 84439 | <1% | 1,332 | $10K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 119 | $9K |
| 83540 | <1% | 1,657 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,453 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 476 | $8K |
| 82607 | <1% | 690 | $8K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 449 | $7K |
| 85652 | <1% | 2,216 | $5K | |
| 87653 | <1% | 141 | $5K | |
| 86850 | <1% | 521 | $4K | |
| 82570 | <1% | 1,129 | $4K | |
| 80076 | <1% | 502 | $4K | |
| 85651 | <1% | 1,099 | $4K | |
| 86901 | <1% | 1,281 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 136 | $3K |
| 83690 | <1% | 370 | $2K | |
| 86160 | <1% | 234 | $2K | |
| 86431 | <1% | 390 | $2K | |
| 82550 | <1% | 345 | $2K | |
| 84403 | <1% | 87 | $2K | |
| 82977 | <1% | 233 | $2K | |
| 85610 | <1% | 469 | $2K | |
| 84156 | <1% | 509 | $2K | |
| 87081 | <1% | 217 | $1K | |
| 86592 | <1% | 253 | $1K | |
| 82950 | <1% | 246 | $1K | |
| 86900 | <1% | 355 | $967.43 | |
| 87420 | <1% | 41 | $635.42 | |
| 83735 | <1% | 141 | $609.80 | |
| 81025 | <1% | 83 | $609.28 | |
| 84436 | <1% | 91 | $607.60 | |
| 82670 | <1% | 13 | $279.40 | |
| 87070 | <1% | 27 | $261.28 | |
| 84702 | <1% | 17 | $225.75 | |
| 84153 | <1% | 12 | $220.68 | |
| 82043 | <1% | 42 | $150.74 | |
| 84100 | <1% | 49 | $150.12 | |
| 84703 | <1% | 14 | $98.96 | |
| 84460 | <1% | 13 | $53.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVANREGENMORTER, ADAM (LABORATORY DIRECTOR)